{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:31Z","timestamp":1789135951287,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Venetoclax is a B-cell lymphoma 2 inhibitor with breakthrough therapy designations and is used in the treatment of acute myeloid leukemia, particularly in patients ineligible for conventional cytotoxic chemotherapy. However, these drugs exhibit extensive pharmacokinetic variability among patients. Therapeutic drug monitoring (TDM) is useful in determining venetoclax dosage regimens. This study aimed to develop a high-throughput method for the quantification of plasma venetoclax concentration using ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS\/MS) and to apply this method to TDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>After a simple solid-phase extraction step using a 96-well \u00b5Elution plate, venetoclax was analyzed using UHPLC-MS\/MS in positive electrospray ionization mode. This novel method fulfilled the requirements of the US Food and Drug Administration guidelines for bioanalytical assay validation, with a 4 ng\/mL lower limit of quantification. The calibration curves were linear over a concentration range of 4\u201350,000 ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The recovery rate was 96.2 \u00b1 18.0% (mean \u00b1 SD). The imprecision was below 7.2% coefficient of variation, and the accuracy was within 10.4% for all quality control levels. The matrix effect varied from 80.6% to 97.9%. This assay was successfully applied to the TDM of trough concentrations in 3 patients treated with venetoclax for acute myeloid leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We successfully developed a novel high-throughput UHPLC-MS\/MS method for quantifying venetoclax in human plasma. This method can be applied for TDM in patients receiving venetoclax in clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001514","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:31:42Z","timestamp":1785533502000},"page":"703-708","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["High-throughput UHPLC-MS\/MS Assay for the Quantification of Venetoclax in Patients with Acute Myeloid Leukemia and Assessment of Clinical Application: A Short Communication"],"prefix":"10.1097","volume":"48","author":[{"given":"Yuri","family":"Hatano","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-1711","authenticated-orcid":false,"given":"Ken","family":"Shiraiwa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sueshige","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Okuhiro","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University Hospital, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University Hospital, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University Hospital, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/030089160909500306","article-title":"Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland","volume":"95","author":"Lerch","year":"2009","journal-title":"Tumori"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Burnett A acute myeloid leukemia","volume":"341","author":"Lowenberg","year":"1999","journal-title":"N Engl J Med."},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199809092687","article-title":"Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group","volume":"28","author":"Bishop","year":"1998","journal-title":"Leuk Lymphoma."},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1600-0609.1991.tb00547.x","article-title":"Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy","volume":"46","author":"Wahlin","year":"1991","journal-title":"Eur J Haematol."},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jbior.2017.05.002","article-title":"Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia","volume":"65","author":"Ricciardi","year":"2017","journal-title":"Adv Biol Regul."},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med."},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","article-title":"Venetoclax in acute myeloid leukemia - current and future directions","volume":"61","author":"Lachowiez","year":"2020","journal-title":"Leuk Lymphoma."},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab Dispos."},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: first global approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-020-04186-0","article-title":"Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia","volume":"99","author":"Megias-Vericat","year":"2020","journal-title":"Ann Hematol."},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"e13807","DOI":"10.1111\/cts.13807","article-title":"Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor","volume":"17","author":"Salem","year":"2024","journal-title":"Clin Transl Sci."},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cpdd.395","article-title":"Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects","volume":"7","author":"Cheung","year":"2018","journal-title":"Clin Pharmacol Drug Dev."},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","article-title":"Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma","volume":"13","author":"Noda","year":"2015","journal-title":"Clin Genitourin Cancer."},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","article-title":"Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors","volume":"152","author":"Terada","year":"2015","journal-title":"Pharmacol Ther."},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000324900","article-title":"Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase","volume":"87","author":"Takahashi","year":"2011","journal-title":"Pharmacology"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejca.2014.04.013","article-title":"Therapeutic drug monitoring in cancer--are we missing a trick?","volume":"50","author":"Bardin","year":"2014","journal-title":"Eur J Cancer."},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/FTD.0000000000001151","article-title":"Pharmacokinetic consideration of venetoclax in acute myeloid leukemia patients: a potential candidate for TDM? A short communication","volume":"46","author":"Philippe","year":"2024","journal-title":"Ther Drug Monit."},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41397-024-00359-6","article-title":"Plasma concentrations of venetoclax and pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study","volume":"24","author":"Li","year":"2024","journal-title":"Pharmacogenomics J."},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpba.2018.11.047","article-title":"Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry","volume":"165","author":"Tanaka","year":"2019","journal-title":"J Pharm Biomed Anal."},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/FTD.0000000000000872","article-title":"A broad range high-throughput assay for lenvatinib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry with clinical application in patients with hepatocellular carcinoma","volume":"43","author":"Sueshige","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"114348","DOI":"10.1016\/j.jpba.2021.114348","article-title":"Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application","volume":"206","author":"Matsumoto","year":"2021","journal-title":"J Pharm Biomed Anal."},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/molecules27051607","article-title":"Quantification of venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method","volume":"27","author":"Yang","year":"2022","journal-title":"Molecules"},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4155\/bio-2021-0207","article-title":"LC-MS\/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction","volume":"14","author":"Reddy","year":"2022","journal-title":"Bioanalysis"},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/pharmaceutics15061680","article-title":"Pharmacokinetics of venetoclax Co-Administered with posaconazole in patients with acute myeloid leukemia","volume":"15","author":"De Gregori","year":"2023","journal-title":"Pharmaceutics"},{"key":"R31-20260911","first-page":"537699","article-title":"Simultaneous determination of venetoclax and posaconazole in human plasma by UPLC-MS\/MS: application to therapeutic drug monitoring in acute myeloid leukemia patients","volume":"20","author":"Chen","year":"2026","journal-title":"Drug Des Devel Ther."},{"key":"R32-20260911","doi-asserted-by":"crossref","first-page":"e5738","DOI":"10.1002\/bmc.5738","article-title":"LC-MS\/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid","volume":"37","author":"Yang","year":"2023","journal-title":"Biomed Chromatogr."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:48Z","timestamp":1789135248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001514","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"2026-04-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}